Unlike scores of people who scrambled for the blockbuster drugs Ozempic and Wegovy to lose weight in recent years, Danielle ...

We recently published a list of 8 Most Promising Healthcare Stocks According to Hedge Funds. In this article, we are going to ...

Critics, including Senator Bernie Sanders, question whether the push to block alternatives is truly about safety — or simply ...

The latest health news highlights FDA's approval of BridgeBio's drug for a rare heart condition, cancer features in healthy ...

Oura smart rings will soon be able to help users track their blood sugar levels through a new partnership with Dexcom (DXCM), ...

Novo Nordisk and Ypsomed’s 2023 deal is rumoured to include an autoinjector supply for potential Wegovy successor CagriSema.

The European Commission is expected to give unconditional approval for the $16.5 billion purchase of Catalent (NYSE: CTLT) as ...

Novo Nordisk's (NVO) contract Ypsomed to supply the company with injection pens designed to deliver its next-gen obesity ...

Swiss medical technology company Ypsomed's contract with Novo Nordisk includes the supply of injection pens for the Danish drugmaker's next-generation experimental obesity drug CagriSema, a source ...

The battle over who should provide obesity and diabetes drugs like Ozempic and Wegovy has reached a critical point, as manufacturers and compounding pharmacies clash over the demand of these ...

Ozempic (semaglutide) is not approved for weight loss but can be prescribed off-label. Wegovy (semaglutide), which is made by the same manufacturer, Novo Nordisk, is FDA-approved for chronic weight ...

New research has found that nearly 137 million adults—or more than half of all U.S. adults—are eligible for semaglutide ...